Choueiri Toni K, Bukowski Ronald M, Rini Brian I
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA.
Semin Oncol. 2006 Oct;33(5):596-606. doi: 10.1053/j.seminoncol.2006.06.003.
Over the last few years, renal cell carcinoma (RCC) has become a model disease for targeted therapeutics based on the growing understanding of the underlying molecular pathways in this disease. Clear cell RCC is characterized by the inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene, which results in the dysregulation of hypoxia response genes, including an overproduction of vascular endothelial growth factor (VEGF), which promotes tumor angiogenesis, growth, and metastasis. In advanced RCC, substantial clinical activity has been reported with VEGF blockade employing a variety of approaches including antibodies and small-molecule VEGF receptor inhibitors. Many trials are still in progress with the goal of defining the optimal utility of these agents as monotherapy or in combination. This review will describe the current clinical data with VEGF-targeted approaches in RCC and plans for future development.
在过去几年中，基于对肾细胞癌（RCC）潜在分子途径的深入了解，它已成为靶向治疗的典型疾病。透明细胞肾细胞癌的特征是von Hippel-Lindau（VHL）肿瘤抑制基因失活，这导致缺氧反应基因失调，包括血管内皮生长因子（VEGF）过度产生，从而促进肿瘤血管生成、生长和转移。在晚期肾细胞癌中，采用多种方法（包括抗体和小分子VEGF受体抑制剂）进行VEGF阻断已报道具有显著的临床活性。许多试验仍在进行中，目标是确定这些药物作为单一疗法或联合疗法的最佳应用。本综述将描述肾细胞癌中VEGF靶向治疗方法的当前临床数据以及未来的发展计划。
